⚠️ JAN 12 – FEB 6 CYBERATTACK: ALL ORDERS REFUNDED • DO NOT PURCHASE UNTIL FURTHER NOTICE • CONTACT support@anubis.estate FOR REFUND STATUS
Phase IThyroid Analog

Compound 61632

Formula Pending

Molecular Mass
N/A
CAS Registry
AUTO-061632
Risk Class
MODERATE
Last Audit
May 16, 2108

Research Abstract

Thyroid Analog candidate engineered for endocrine support initiatives with automated dossier coverage.

Compound 61632 is a thyroid analog asset inside thyroid analog innovation track initiatives, optimized for endocrine support and performance longevity.

The dossier currently sits in phase i with a moderate risk rating, meaning it is requires layered oversight with metabolic labs.

Supply records cite CAS AUTO-061632 with updates logged 2108-05-16.

Acquisition Protocol

Authorized research personnel may request deployment of this compound for laboratory analysis.

Primary Vectors

Endocrine supportPerformance longevity

Nomenclature

CX-61632Thyroid Analog Program 61632

Reference Material

  1. [1] Anubis Compound Registry • CAS AUTO-061632
  2. [2] Operations Pulse • Thyroid Analog innovation track
  3. [3] Risk Governance Ledger • MODERATE clearance for COMPOUND-61632